|
Iray Technology Company Limited (688301.SS) Valoración de DCF
CN | Healthcare | Medical - Instruments & Supplies | SHH
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
iRay Technology Company Limited (688301.SS) Bundle
¡Obtenga dominio sobre su análisis de valoración de Iray Technology Company (688301SS) con nuestra sofisticada calculadora DCF! Esta plantilla de Excel viene precargada con datos reales (688301SS), lo que le permite ajustar los pronósticos y los supuestos para determinar con precisión el valor intrínseco de Iray Technology Company Limited.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 546.1 | 784.1 | 1,187.4 | 1,549.1 | 1,863.8 | 2,543.1 | 3,470.0 | 4,734.7 | 6,460.3 | 8,815.0 |
| Revenue Growth, % | 0 | 43.58 | 51.43 | 30.47 | 20.31 | 36.45 | 36.45 | 36.45 | 36.45 | 36.45 |
| EBITDA | 113.9 | 283.3 | 592.3 | 773.1 | 785.7 | 1,011.8 | 1,380.6 | 1,883.8 | 2,570.4 | 3,507.2 |
| EBITDA, % | 20.85 | 36.14 | 49.88 | 49.91 | 42.15 | 39.79 | 39.79 | 39.79 | 39.79 | 39.79 |
| Depreciation | 6.8 | 25.3 | 33.3 | 51.6 | 73.8 | 74.1 | 101.2 | 138.0 | 188.3 | 257.0 |
| Depreciation, % | 1.25 | 3.23 | 2.8 | 3.33 | 3.96 | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 |
| EBIT | 107.0 | 258.0 | 559.0 | 721.5 | 711.9 | 937.7 | 1,279.4 | 1,745.7 | 2,382.0 | 3,250.2 |
| EBIT, % | 19.6 | 32.91 | 47.08 | 46.58 | 38.2 | 36.87 | 36.87 | 36.87 | 36.87 | 36.87 |
| Total Cash | 136.0 | 2,337.8 | 2,260.7 | 3,374.3 | 2,150.1 | 2,161.1 | 2,948.8 | 4,023.6 | 5,490.1 | 7,491.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 208.2 | 183.0 | 397.7 | 408.7 | 680.0 | 802.8 | 1,095.4 | 1,494.6 | 2,039.4 | 2,782.6 |
| Account Receivables, % | 38.13 | 23.34 | 33.49 | 26.38 | 36.48 | 31.57 | 31.57 | 31.57 | 31.57 | 31.57 |
| Inventories | 126.2 | 173.0 | 329.6 | 657.7 | 781.8 | 800.3 | 1,091.9 | 1,489.9 | 2,033.0 | 2,773.9 |
| Inventories, % | 23.11 | 22.06 | 27.76 | 42.46 | 41.95 | 31.47 | 31.47 | 31.47 | 31.47 | 31.47 |
| Accounts Payable | 130.5 | 75.0 | 134.5 | 228.2 | 776.1 | 514.5 | 702.0 | 957.9 | 1,307.0 | 1,783.4 |
| Accounts Payable, % | 23.9 | 9.56 | 11.33 | 14.73 | 41.64 | 20.23 | 20.23 | 20.23 | 20.23 | 20.23 |
| Capital Expenditure | -40.1 | -16.9 | -191.7 | -717.3 | -1,853.6 | -871.7 | -1,189.4 | -1,623.0 | -2,214.5 | -3,021.6 |
| Capital Expenditure, % | -7.34 | -2.15 | -16.15 | -46.31 | -99.45 | -34.28 | -34.28 | -34.28 | -34.28 | -34.28 |
| Tax Rate, % | 11.31 | 11.31 | 11.31 | 11.31 | 11.31 | 11.31 | 11.31 | 11.31 | 11.31 | 11.31 |
| EBITAT | 100.2 | 225.5 | 483.2 | 652.9 | 631.4 | 837.6 | 1,142.9 | 1,559.5 | 2,127.8 | 2,903.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -137.0 | 156.9 | 13.1 | -258.2 | -996.1 | -362.7 | -342.1 | -466.8 | -637.0 | -869.1 |
| WACC, % | 5.91 | 5.87 | 5.86 | 5.89 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,201.0 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -900 | |||||||||
| Terminal Value | -37,794 | |||||||||
| Present Terminal Value | -28,402 | |||||||||
| Enterprise Value | -30,603 | |||||||||
| Net Debt | 261 | |||||||||
| Equity Value | -30,864 | |||||||||
| Diluted Shares Outstanding, MM | 106 | |||||||||
| Equity Value Per Share | -292.13 |
What You Will Receive
- Real iRay Financial Data: Pre-loaded with historical and projected figures for comprehensive analysis of iRay Technology Company Limited (688301SS).
- Fully Customizable Template: Easily adjust essential inputs like revenue growth, WACC, and EBITDA percentage.
- Instantaneous Calculations: Watch as the intrinsic value of iRay updates in real-time with your modifications.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for accurate DCF outcomes.
- User-Friendly Interface: Clear layout and straightforward instructions suitable for users of all experience levels.
Key Features of iRay Technology Company Limited (688301SS)
- Customizable Forecast Inputs: Adjust essential parameters such as revenue growth, EBITDA percentage, and capital expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial metrics.
- Precision Fit for Professionals: Leverages real financial data from iRay for accurate valuation results.
- Simplified Scenario Analysis: Effortlessly evaluate various assumptions and analyze outcomes side by side.
- Efficiency Booster: Streamlines the valuation process, eliminating the need to construct intricate models from the ground up.
How It Functions
- 1. Access the Template: Download and open the Excel file containing iRay Technology Company Limited’s (688301SS) preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures.
- 3. See Instant Results: The DCF model automatically calculates intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation scenarios.
- 5. Approach with Certainty: Deliver professional valuation insights to enhance your decision-making process.
Why Opt for iRay Technology's Calculator?
- Time-Efficient: Skip the hassle of building a DCF model from scratch – it’s ready for immediate use.
- Enhanced Precision: Dependable financial data and formulas minimize valuation errors.
- Completely Customizable: Adjust the model to align with your assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify the analysis of results.
- Endorsed by Professionals: Created for experts who prioritize accuracy and functionality.
Who Should Utilize This Product?
- Investors: Accurately assess the fair value of iRay Technology Company Limited (688301SS) prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for comprehensive financial reporting and analysis.
- Consultants: Efficiently customize the template for valuation reports tailored to clients.
- Entrepreneurs: Discover financial modeling techniques utilized by leading companies.
- Educators: Employ it as a resource to illustrate valuation methods in the classroom.
Contents of the Template
- Pre-Filled DCF Model: iRay Technology Company Limited’s financial data preloaded for immediate analysis.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess iRay Technology's profitability, leverage, and operational efficiency.
- Editable Inputs: Adjust assumptions such as growth rates, profit margins, and capital expenditures to suit your projections.
- Financial Statements: Access annual and quarterly reports for in-depth analysis.
- Interactive Dashboard: Effortlessly visualize vital valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.